However, as with alteration of radiotracer size for protein-based compounds, the addition of HSA-binding tags does not facilitate tissue-specific control over pharmacokinetics, especially in terms of retaining high tumour uptake and selectivity reducing activity accumulation in background organs. The gene discussed is ALB; the disease is neoplasm.